Dermira (DERM) Says Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
Tweet Send to a Friend
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to delivering new therapies to patients living with chronic skin conditions, today ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
